Summary
• Anixa Biosciences’ stock rises 6.7% to $5.12 following positive Phase 1 clinical trial data for its breast cancer vaccine.
• The trial demonstrated a 74% immune response rate and safe tolerability, leading to plans for Phase 2 development.
• Analysts maintain a “Buy” rating, reflecting a positive outlook amid notable quarterly and year-to-date stock gains of 63.3% and 106.9%, respectively.
Anixa Biosciences, Inc. (ANIX) is seeing a robust pre-market rally, trading at $5.12, marking a 6.7% increase from its last close of $4.80. This upward movement comes on the heels of significant news, indicating a potentially positive shift in investor sentiment toward the company’s developments.
Positive Phase 1 Data Spurs Investor Interest
The surge in Anixa’s stock price follows the announcement of promising data from a Phase 1 clinical trial of its investigational breast cancer vaccine. The company reported that primary endpoints were met, with an immune response observed in 74% of participants. The vaccine was deemed safe and well-tolerated, encouraging plans to proceed into Phase 2 development, which will involve a combination study with Keytruda in newly diagnosed breast cancer patients. The data was presented at the 2025 San Antonio Breast Cancer Symposium on December 11, 2025.
Trading and Performance Metrics
Currently, Anixa shows a notable quarterly performance increase of 63.3%, coupled with a year-to-date gain of 106.9%. The stock’s volatility metrics indicate a weekly volatility of 6.75%, suggesting some fluctuations in price. With an average volume of 397,148 over the last 10 days, traders are paying close attention to its movements leading into the next session.
The company’s RSI stands at 55.54, indicating that it is neither overbought nor oversold, which could provide room for further growth if the upward momentum continues.
Analyst Sentiment
Anixa currently holds a “Buy” rating from analysts, suggesting a generally positive outlook on the stock. This ratings sentiment, coupled with the recently unveiled trial results, may further encourage investors to consider the viability of the company’s product offerings.
Closing Thoughts
With the latest update now reflected in trading, investors appear to be reassessing the company’s growth profile in light of its advancing vaccine development for breast cancer. This positive market reaction underscores heightened interest in Anixa’s innovative approaches and the potential for significant advancements in cancer treatment strategies.